Category: MS Research Study and Reports

Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies

 ORIGINAL RESEARCH article –  Front. Immunol., 05 August 2022    https://doi.org/10.3389/fimmu.2022.926318   — Sec. Vaccines and Molecular Therapeutics –   —————————————– https://www.frontiersin.org/journals/immunology…

Stuart Schlossman

Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability

Abstract Objective: We sought to characterize spinal cord atrophy along the entire spinal cord in the major multiple sclerosis (MS) phenotypes,…

Stuart Schlossman

Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study

 Elia Sechi 1, Steven Messina 2, B Mark Keegan 1, Marina Buciuc 1, Sean J Pittock 3, Orhun H Kantarci…

Stuart Schlossman

Video: Learning about The CASA-MS study, a Comprehensive Assessment of Severely Affected Multiple Sclerosis

  Click to Subscribe for the MS Beacon eNewsletter and MS educational events Visit our MS Learning Channel on YouTube:…

Stuart Schlossman

Rituximab Outperforms Tecfidera at Preventing Relapses in Phase 3 Trial

 by Marisa Wexler, MS | July 15, 2022 Patients on rituximab MS treatment 5 times less likely to experience relapse…

Stuart Schlossman

EDSS ‘0’ is not normal: Multiple sclerosis disease burden below the clinical threshold

2022 Jul 13;13524585221108297 –   doi: 10.1177/13524585221108297. Online ahead of print.  Stephen C Krieger 1, Ali Antoine 1, James F Sumowski 1 PMID: 35832024   DOI: 10.1177/13524585221108297 #MS disability…

Stuart Schlossman

Health Care Utilization, Prodromal Symptoms Prior to Pediatric-Onset MS

 By Sheila Jacobs – June 7, 2022 Neurologic complaints included headache, sensory symptoms, visual symptoms, and motor symptoms in the 2…

Stuart Schlossman

Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?

 June 8, 2022 – Mary Stroka The most frequent AEs were flushing (32.3%), nasopharyngitis (24.6%), and MS relapse during treatment with…

Stuart Schlossman

Ocrelizumab Reduces Thalamic Volume Loss

Ocrelizumab Reduces Thalamic Volume Loss, – Cenobamate Shines in C017 Study, Trial of LRRK2 Inhibitor BIIB122 Commences Using the phase 3…

Stuart Schlossman

Media Update: Patient enrollment of phase III tolebrutinib trials paused in the U.S.

 Paris, June 30, 2022. The U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS)…

Stuart Schlossman

Categories

Latest Blog Posts